478 related articles for article (PubMed ID: 33820953)
1. How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer.
Stultz J; Fong L
Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):697-717. PubMed ID: 33820953
[TBL] [Abstract][Full Text] [Related]
2. Single-Cell Analysis Reveals EP4 as a Target for Restoring T-Cell Infiltration and Sensitizing Prostate Cancer to Immunotherapy.
Peng S; Hu P; Xiao YT; Lu W; Guo D; Hu S; Xie J; Wang M; Yu W; Yang J; Chen H; Zhang X; Zhu Y; Wang Y; Yang Y; Zhu G; Chen S; Wang J; Zhang B; Chen W; Wu H; Sun Z; Ding T; Zhang H; Yi Z; Liu M; Ren S
Clin Cancer Res; 2022 Feb; 28(3):552-567. PubMed ID: 34740924
[TBL] [Abstract][Full Text] [Related]
3. Prostate Cancer Immunotherapy-Finally in From the Cold?
Runcie KD; Dallos MC
Curr Oncol Rep; 2021 Jun; 23(8):88. PubMed ID: 34125308
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer immunotherapy: where are we and where are we going?
De Velasco MA; Uemura H
Curr Opin Urol; 2018 Jan; 28(1):15-24. PubMed ID: 29095729
[TBL] [Abstract][Full Text] [Related]
5. Refining Immuno-Oncology Approaches in Metastatic Prostate Cancer: Transcending Current Limitations.
Wong RL; Yu EY
Curr Treat Options Oncol; 2021 Jan; 22(2):13. PubMed ID: 33433743
[TBL] [Abstract][Full Text] [Related]
6. Immunological Complexity of the Prostate Cancer Microenvironment Influences the Response to Immunotherapy.
Prokhnevska N; Emerson DA; Kissick HT; Redmond WL
Adv Exp Med Biol; 2019; 1210():121-147. PubMed ID: 31900908
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy in treatment of metastatic prostate cancer: An approach to circumvent immunosuppressive tumor microenvironment.
Sun BL
Prostate; 2021 Nov; 81(15):1125-1134. PubMed ID: 34435699
[TBL] [Abstract][Full Text] [Related]
8. Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer.
Rathi N; McFarland TR; Nussenzveig R; Agarwal N; Swami U
Drugs; 2021 Feb; 81(2):191-206. PubMed ID: 33369720
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy for prostate cancer: False promises or true hope?
Rekoske BT; McNeel DG
Cancer; 2016 Dec; 122(23):3598-3607. PubMed ID: 27649312
[TBL] [Abstract][Full Text] [Related]
10. Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies.
Datta M; Coussens LM; Nishikawa H; Hodi FS; Jain RK
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():165-174. PubMed ID: 31099649
[TBL] [Abstract][Full Text] [Related]
11. The Tumor Microenvironment and Immunotherapy in Prostate and Bladder Cancer.
Nair SS; Weil R; Dovey Z; Davis A; Tewari AK
Urol Clin North Am; 2020 Nov; 47(4S):e17-e54. PubMed ID: 33446323
[TBL] [Abstract][Full Text] [Related]
12. A comprehensive review of immunotherapies in prostate cancer.
Maia MC; Hansen AR
Crit Rev Oncol Hematol; 2017 May; 113():292-303. PubMed ID: 28427519
[TBL] [Abstract][Full Text] [Related]
13. Understanding the tumor-immune microenvironment in prostate cancer.
Dong L; Myers KV; Pienta KJ
Curr Opin Oncol; 2021 May; 33(3):231-237. PubMed ID: 33606403
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy in Advanced Prostate Cancer-Light at the End of the Tunnel?
von Amsberg G; Alsdorf W; Karagiannis P; Coym A; Kaune M; Werner S; Graefen M; Bokemeyer C; Merkens L; Dyshlovoy SA
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269712
[TBL] [Abstract][Full Text] [Related]
15. Utilizing precision medicine to modulate the prostate tumor microenvironment and enhance immunotherapy.
Olson B; Patnaik A
Urol Oncol; 2019 Aug; 37(8):535-542. PubMed ID: 30503851
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy of prostate cancer: identification of new treatments and targets for therapy, and role of WAP domain-containing proteins.
Galustian C; Vyakarnam A; Elhage O; Hickman O; Dasgupta P; Smith RA
Biochem Soc Trans; 2011 Oct; 39(5):1433-6. PubMed ID: 21936828
[TBL] [Abstract][Full Text] [Related]
17. Cutibacterium acnes Induces the Expression of Immunosuppressive Genes in Macrophages and is Associated with an Increase of Regulatory T-Cells in Prostate Cancer.
Davidsson S; Carlsson J; Greenberg L; Wijkander J; Söderquist B; Erlandsson A
Microbiol Spectr; 2021 Dec; 9(3):e0149721. PubMed ID: 34937192
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant therapy for localized prostate cancer: Examining mechanism of action and efficacy within the tumor.
Lou DY; Fong L
Urol Oncol; 2016 Apr; 34(4):182-92. PubMed ID: 24495446
[TBL] [Abstract][Full Text] [Related]
19. Multi-faceted immunomodulatory and tissue-tropic clinical bacterial isolate potentiates prostate cancer immunotherapy.
Anker JF; Naseem AF; Mok H; Schaeffer AJ; Abdulkadir SA; Thumbikat P
Nat Commun; 2018 Apr; 9(1):1591. PubMed ID: 29686284
[TBL] [Abstract][Full Text] [Related]
20. The requirement for immune infiltration and organization in the tumor microenvironment for successful immunotherapy in prostate cancer.
Jansen CS; Prokhnevska N; Kissick HT
Urol Oncol; 2019 Aug; 37(8):543-555. PubMed ID: 30446449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
